Compare Amgen, Inc. (AMGN) vs Norfolk Southern Corporation (NSC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Norfolk Southern Corporation — how do they compare? Amgen, Inc. trades at $362.14 (market cap $196.12B), while Norfolk Southern Corporation trades at $332.51 (market cap $73.55B). The key difference: Amgen, Inc. is far larger — about 2.7× Norfolk Southern Corporation's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | NSC | |
|---|---|---|
Market Cap | $196.12B | $73.55B |
Sector | Health | Technology |
52-Week High | $388.16 | $327.47 |
52-Week Low | $271.18 | $259.49 |
Enterprise Value | $241.41B | $89.31B |
Dividend Yield | 2.77% | 1.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Norfolk Southern (NSC) trades at $327.47, up 1.14% with a bullish technical outlook and strong fundamental performance. The stock shows consistent earnings beats, with Q1 2026 EPS of $2.65 exceeding expectations of $2.49. Valuation metrics include a P/E of 27.59 and ROE of 17.6%, while analyst consensus targets $342.67. Recent developments include the pending merger with Union Pacific and upcoming Q2 2026 earnings on July 23, 2026.
NSC presents a favorable investment case with strong profitability and merger potential, though regulatory scrutiny and rich valuations pose risks. The stock's proximity to 52-week highs suggests limited near-term upside, but long-term growth prospects remain solid if merger approvals proceed smoothly and operational efficiency improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →
